Memories (Q4300746)
Jump to navigation
Jump to search
Project Q4300746 in Belgium, Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Memories |
Project Q4300746 in Belgium, Netherlands |
Statements
778,161.27 Euro
0 references
2,409,168.02 Euro
0 references
32.3 percent
0 references
1 January 2018
0 references
30 June 2021
0 references
ToxGenSolutions BV
0 references
50°51'59.36"N, 4°40'27.52"E
0 references
50°52'41.16"N, 4°41'58.96"E
0 references
50°53'19.25"N, 4°42'21.38"E
0 references
51°9'37.87"N, 4°24'22.57"E
0 references
50°50'0.10"N, 5°42'57.85"E
0 references
50°50'9.06"N, 5°42'59.08"E
0 references
50°50'12.59"N, 5°43'0.01"E
0 references
Neurodegenerative diseases such as Parkinson's, multiple sclerosis and Alzheimer's disease are known for the intensive care and associated hospitalizations. Early diagnosis and effective treatment methods are therefore necessary to reduce health care costs and improve the quality of life of patients and their families. 'Herinneringen' takes Alzheimer's disease as 'proof-of-concept'. In about 5 out of 100 families in which the disease begins before the age of 65, the cause is usually hereditary. However, there are young patients without these genetic risk factors which would suggest that unprecedented genes and/or external factors play a role. The majority, however, develops symptoms in old age, usually after the age of 60 years old. This type of Alzheimer's does not have a genetic background. It is assumed that there is an accumulation of changes in the genetic material due to age and influencing risk factors such as chemicals (heavy metals, pesticides, anaesthetics) and lifestyle (obesity). The mechanisms by which these risk factors drive the further development of the disease will be investigated in 'Herinneringen' and applied in new diagnostic methods and therapies. The project focuses among other things on being able to make early diagnostics. For example, the Icometrix software, which was originally developed for measuring brain deformations in multiple sclerosis, will be adapted for use on patients with Alzheimer's disease. The principle is that images from MRI brain scans can be converted into numbers, comparable with the numerical values of a blood test. In this way, more precise measurements can be made. These data are further evaluated to optimize the diagnosis, follow-up and prognosis of Alzheimer's disease. (English)
0 references